Testing a new medicine for healthy adults
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new investigational drug called GV-100 to see how safe it is and how the body handles it. It is for healthy adults and will be given in different doses to find the best one.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must be a healthy non-smoker.
- Your body mass index (BMI) must be between 18.0 and 32.0, and you must weigh at least 50 kg.
- You cannot have any significant medical conditions or take most prescription or over-the-counter medicines.
- You must not have participated in another clinical trial recently or have been exposed to GV-100 before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug (JMKX003142) for people with autosomal dominant polycystic kidney disease that is getting worse quickly. It may help slow down kidney damage.
This study checks how a new drug interacts with the body. It is for healthy volunteers to see if the drug is safe and how it works in the body.
This study is for healthy Chinese men to see how the study drug JMKX003142 is processed in the body. You will take the drug by mouth and by vein on separate days to measure how much gets into your blood and how it leaves your body.
This early-stage study tests how a new experimental drug (JMKX003142) interacts with other medications in healthy volunteers. Researchers want to understand whether taking this drug with other common drugs is safe and effective.
This is an early-stage study testing a new investigational drug called IG001119 in people who are in good health. Researchers will give increasing doses to small groups to learn how the drug is processed by the body and to check for any side effects.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
Hear when a new ADPKD (Autosomal Dominant Polycystic Kidney Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.